Completed

NCT Number: NCT03866824

MENIPREP Study: Evauation of the Effectiveness of Prp Injection in the Management of Degenerative Meniscal Lesions : Randomized Controlled Trial Double Blind Versus Reference Treatment"

Meniscal tissue has very limited intrinsic properties in terms of repair, given the low mitotic activity of chondrocytes and poor vascularization. Nevertheless, its capacity for regeneration, in vivo and in vitro, can be stimulated by the contribution of growth factors, as has been widely described in the medical and scientific literature. Platelet Enhanced Plasma (PRP) is an autologous biological product (that is, derived from the patient's blood) containing a growth factor concentrate. The contribution of these growth factors stimulates cartilage repair by stimulating neovascularization, collagen synthesis and activation of chondrocytes. Intra-articular injection PRP is an autologous biological product, now used in daily practice for the treatment of early osteoarthritic lesions.

The hypothesis of this work is that the injection of PRP in contact with LMD(Degenerative Meniscal Lesions) will improve the clinical symptomatology of our patients compared to reference treatment (intra-auricular injection of corticosteroids).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

DEGENERATIVE MENISCAL LESIONS

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Assistance Publique Hopitaux de Marseille

Marseille, 13354, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men and women aged 20 to 80

MDD diagnosis objected to MRI (grade II/III)
Joint pain for more than 3 month
Absence of bone lesion or moderate knee osteoarthritis stage <2 on the Kellgren Laurence scale (objectified on radiography in schuss) in the 6 months prior to inclusion
Axial deformity of the lower limbs less than or equal to 5 °
Signed consent signed by the patient
Ability to perform procedures as part of the follow-up (walk 50 steps on a flat surface and up / down stairs).
Be affiliated to a health insurance scheme

Exclusion criteria

Axial deformity> 5 °
Ligament instability
Major injuries or surgery of the target knee or lateral contralateral knee in the 12 months preceding the inclusion visit
Ligament reconstruction in the 12 months prior to the inclusion visit
Need a cane or assistance to move
BMI> 35
Thrombocytopenia <150 G / L
Thrombocytosis> 450 G / L

Treatment and study plan

injection of Platelet Enhanced Plasma(PRP)

Drug

intra-articular injection

injection of corticosteroids

Drug

intra-articular injection

RMI

Device

A CONTROL RMI at 1 year follow-up.

Primary outcomes

Control by Magnetic Resonance Imaging (MIR)

Time frame: 12 Months

To evaluate the evolution of the LMD compared to pretherapeutic images.

Secondary outcomes

self-completed questionnaire EVA score

Time frame: 12 Months

EVA (analogical visual scale)
self-completed questionnaire SF36

Time frame: 12 Months

SF36 (The Short Form (36) Health Survey)
self-completed questionnaire KOOS score

Time frame: 12 Months

KOOS (Knee Injury and Osteoarthritis Outcome Score)

Sponsors and collaborators

Lead sponsor

Assistance Publique Hopitaux De Marseille

Other

Registry information

Acronym: MENIPREP

Important dates

Study start: 2019
Primary completion: 2021
Study completion: 2023
First posted: Mar 7, 2019
Registry last updated: Jun 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.